期刊
IMMUNOTHERAPY
卷 12, 期 14, 页码 1047-1052出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0116
关键词
CAR-T cells; CRS; ruxolitinib
类别
资金
- National Key Research and Development Program of China [2017YFC0909800]
- National Natural Science Foundation of China [81830005]
- CAMS Innovation Fund for Medical Sciences [CIFMS 2016-I2M-1-001]
- Celgene
Aim:Although numerous pro-inflammatory cytokines promote signaling via intracellular pathways involving Janus kinases, it remains unclear if ruxolitinib, a Janus kinase1/2 inhibitor, provides control of cytokine-release syndrome (CRS) without toxicity against therapeutic T cells.Materials & methods:We report successful clinical experience using ruxolitinib as adjuvant therapy to treat steroid-refractory CRS, which was related to CD22/CD19 chimeric antigen receptor-modified T cell sequential infusion, in a patient with Philadelphia chromosome-like acute lymphoblastic leukemia.Results:His symptoms improved rapidly after first dose of ruxolitinib; this was associated with reduced levels of circulating pro-inflammatory indicators. He eventually achieved minimal residual disease negative remission.Discussion:This is the first case in which ruxolitinib was used to treat steroid-refractory CRS; furthermore, this intervention had no apparent impact on the antileukemic actions of the chimeric antigen receptor-modified T cells. Our results suggest that adjuvant ruxolitinib therapy may be an alternative therapeutic approach for the management of CRS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据